Contact
Please use this form to send email to PR contact of this press release:
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
TO:
Please use this form to send email to PR contact of this press release:
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
TO: